By bringing together powerful players from science and industry with complementary skills, we are meeting the challenge of tailoring the treatment of atherothrombosis-related cardiovascular diseases.
Cluster for atherothrombosis and individualized medicine - An association of various partners from academia and industry in the Rhine-Main-Palatinate region.
In 17 collaborative projects, individualized therapies against atherothrombosis are developed with the help of new research approaches and artificial intelligence.
News & Events
curAMeet 2024 - Our first curATime Cluster Conference
curATalk Stefan Engelhardt - 15.01.2024
In curATime, we want to use artificial intelligence to identify disease-relevant factors that link to causes of atherothrombosis. Furthermore, we want to identify molecularly defined precision interventions and hope that by applying these we will be able to reduce the incidence and impact of cardiovascular diseases and therefore to significantly reduce mortality in the population.
Atherothrombosis is the world's No. 1 cause of death
Death rates continue to rise every year
In addition to the high mortality rate, cardiovascular diseases can severely impair the quality of life of those affected by it.
No significant progress has been made in medical research in recent decades
There is an urgent need for new, personalized therapy options
Precise targeting of disease-relevant mechanisms through AI- and mRNA-based technologies.
For this purpose, individualized and subgroup-specific profiles for atherosclerotic biomarkers and risks will be developed using AI-supported and state-of-the-art bioinformatics. The findings will be used to develop innovative diagnostic, preventive and therapeutic concepts. This includes the generation of novel algorithms to improve therapy selection and risk assessment as well as eHealth apps and smart devices. Central to the success of the cluster are large data sets from representative population studies and their computer-based analysis using artificial intelligence.